NTV Asset Management LLC Sells 566 Shares of Becton, Dickinson and Company $BDX

NTV Asset Management LLC decreased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 17.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,672 shares of the medical instruments supplier’s stock after selling 566 shares during the quarter. NTV Asset Management LLC’s holdings in Becton, Dickinson and Company were worth $460,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of BDX. Northcape Wealth Management LLC boosted its holdings in Becton, Dickinson and Company by 0.5% in the first quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier’s stock valued at $2,248,000 after acquiring an additional 51 shares during the last quarter. Alpha Omega Wealth Management LLC lifted its position in shares of Becton, Dickinson and Company by 5.7% in the 1st quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier’s stock worth $225,000 after purchasing an additional 53 shares during the period. Brady Family Wealth LLC boosted its stake in shares of Becton, Dickinson and Company by 1.2% in the 1st quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier’s stock valued at $989,000 after purchasing an additional 53 shares during the last quarter. Diversified Trust Co increased its position in shares of Becton, Dickinson and Company by 4.7% during the first quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier’s stock worth $272,000 after buying an additional 53 shares during the period. Finally, Horizon Bancorp Inc. IN raised its stake in Becton, Dickinson and Company by 10.9% during the first quarter. Horizon Bancorp Inc. IN now owns 569 shares of the medical instruments supplier’s stock worth $130,000 after buying an additional 56 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Insider Activity at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director owned 22,226 shares in the company, valued at $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of the company’s stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the sale, the executive vice president owned 4,887 shares of the company’s stock, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 3,023 shares of company stock valued at $562,036. Company insiders own 0.36% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Saturday, September 27th. Argus raised their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Morgan Stanley increased their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Finally, Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $205.40.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $193.67 on Friday. The company has a fifty day simple moving average of $189.03 and a 200 day simple moving average of $187.38. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The company has a market cap of $55.51 billion, a P/E ratio of 34.83, a PEG ratio of 1.51 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.28. The firm had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business’s revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Sell-side analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company’s payout ratio is currently 74.82%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.